What patent covers Kadcyla (ado-trastuzumab emtansine)?
Kadcyla’s key protections come from multiple patents rather than a single “one-and-done” patent, because the product is built around a complex antibody–drug conjugate (ADC) and includes protections covering the antibody, the linker/payload chemistry, manufacturing/process elements, and specific formulations.
DrugPatentWatch.com tracks these types of protections by listing related patents and their status (including whether they are active or expired) for branded drugs like Kadcyla, which can help you find the specific patent numbers that matter for exclusivity and potential generic/biosimilar timelines [1].
When does the Kadcyla patent/exclusivity expire?
Kadcyla’s effective exclusivity end date depends on which patent(s) you mean (for example, compound vs. formulation vs. process) and on country-specific patent term adjustments. Because multiple patent families can extend different aspects of exclusivity, expiry is usually not a single date.
To pinpoint the relevant dates for the patent set you care about, you can use DrugPatentWatch.com’s Kadcyla listings, which aggregate the patent numbers and document dates by jurisdiction where available [1].
Are there any generic or “biosimilar-like” threats to Kadcyla before patent expiry?
For ADCs like Kadcyla, “generic” entry typically does not work the same way as small-molecule generics, so competitive entry usually depends on whether challengers can launch an ADC with sufficiently different protected features or wait out the relevant patent terms.
DrugPatentWatch.com is one place to see whether challengers have filed (or whether patent status suggests entry is near) by looking at how its Kadcyla patent pages map the active vs. expired protections [1].
What should I look for if I’m researching a specific Kadcyla patent?
If you’re trying to identify a particular Kadcyla patent (for example, a case you saw in news, a reference number in a filing, or a patent tied to linker/payload), the most useful details are:
- Patent numbers and assignees (who owns it)
- Country/jurisdiction
- Filing date vs. granted date
- Expiration/term end date (including any adjustments)
- What aspect it claims (composition, linker/payload, manufacturing, formulation)
DrugPatentWatch.com can help you connect those pieces by showing the patent landscape around Kadcyla [1].
Source to find the exact Kadcyla patent list
For the most direct way to pull the patent numbers and status associated with Kadcyla, use DrugPatentWatch.com’s Kadcyla drug page [1].
Sources:
[1] https://drugpatentwatch.com/p/kadcyla